IMR Press / FBL / Volume 24 / Issue 4 / DOI: 10.2741/4742

Frontiers in Bioscience-Landmark (FBL) is published by IMR Press from Volume 26 Issue 5 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with Frontiers in Bioscience.

GCPII and its close homolog GCPIII: from a neuropeptidase to a cancer marker and beyond
Show Less
1 Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Flemingovo n. 2, Prague 6, 16610, Czech Republic
2 First Faculty of Medicine, Charles University, Katerinska 32, Prague 2, 12108, Czech Republic
3 Department of Biochemistry, Faculty of Science, Charles University, Albertov 6, Prague 2, 12843, Czech Republic
*Correspondence: (Jan Konvalinka)
Front. Biosci. (Landmark Ed) 2019, 24(4), 648–687;
Published: 1 March 2019
(This article belongs to the Special Issue Dipeptidyl peptidase IV and related molecules in health and disease)

Glutamate carboxypeptidases II and III (GCPII and GCPIII) are highly homologous di-zinc metallopeptidases belonging to the M28 family. These enzymes are expressed in a variety of tissues, including the brain, prostate, kidney, testis and jejunum. GCPII has been recognized as a neuropeptidase in the central nervous system, as a folate hydrolase participating in absorption of folates in the jejunum and, most importantly, as a prostate-specific membrane antigen that is highly expressed in prostate adenocarcinoma. Furthermore, it has been identified in the neovasculature of most human solid tumors. In contrast, GCPIII has not been associated with any specific physiological function or pathology, and its expression, activity and inhibition have not been as well-studied. In this review, we provide an overview of the current understanding of the structure, enzymatic activity, substrate specificity, and tissue distribution of these two homologous enzymes. We discuss their potential physiological functions and describe the available animal models, including genetically modified mice. We also review the potential use of specific monoclonal antibodies and small-molecule inhibitors recognizing GCPII/III for diagnosis, imaging and experimental therapy of human cancers and other pathologies.

Figure 1
Back to top